ATE329913T1 - Oxazole als mglur1 verstärker - Google Patents

Oxazole als mglur1 verstärker

Info

Publication number
ATE329913T1
ATE329913T1 AT03795907T AT03795907T ATE329913T1 AT E329913 T1 ATE329913 T1 AT E329913T1 AT 03795907 T AT03795907 T AT 03795907T AT 03795907 T AT03795907 T AT 03795907T AT E329913 T1 ATE329913 T1 AT E329913T1
Authority
AT
Austria
Prior art keywords
mglur1
oxazoles
amplifier
mglur1 amplifier
Prior art date
Application number
AT03795907T
Other languages
English (en)
Inventor
Joerg Huwyler
Frederic Knoflach
Eric Vieira
Juergen Wichmann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE329913T1 publication Critical patent/ATE329913T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03795907T 2002-12-23 2003-12-17 Oxazole als mglur1 verstärker ATE329913T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02028747 2002-12-23

Publications (1)

Publication Number Publication Date
ATE329913T1 true ATE329913T1 (de) 2006-07-15

Family

ID=32668736

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03795907T ATE329913T1 (de) 2002-12-23 2003-12-17 Oxazole als mglur1 verstärker

Country Status (16)

Country Link
US (1) US7119113B2 (de)
EP (1) EP1578746B1 (de)
JP (1) JP4286788B2 (de)
KR (1) KR100713265B1 (de)
CN (1) CN100336813C (de)
AR (1) AR042643A1 (de)
AT (1) ATE329913T1 (de)
AU (1) AU2003298195B8 (de)
BR (1) BR0317714A (de)
CA (1) CA2511337C (de)
DE (1) DE60306202T2 (de)
ES (1) ES2265600T3 (de)
MX (1) MXPA05006657A (de)
PL (1) PL211061B1 (de)
RU (1) RU2345076C2 (de)
WO (1) WO2004056814A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2534529A1 (en) * 2003-08-06 2005-02-24 Pfizer Products Inc. Oxazole compounds for the treatment of neurodegenerative disorders
TW200732313A (en) * 2005-12-15 2007-09-01 Astrazeneca Ab Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators
TW200845978A (en) * 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
WO2009098455A1 (en) * 2008-02-06 2009-08-13 Astrazeneca Ab 2- (9h-xanthen-9-yl) -oxazol derivatives as m3 muscarinic receptor antagonists for the treatment of asthma and chronic obstructive lung disease
CN103319447B (zh) * 2013-06-18 2015-05-20 烟台万润精细化工股份有限公司 一种呫吨-9-羧酸的制备方法
US20210161910A1 (en) * 2019-12-02 2021-06-03 University Of Connecticut Combining BACE1 Inhibitors With mGluR Agonists For Alzheimer's Disease Therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW593241B (en) * 1999-04-20 2004-06-21 Hoffmann La Roche Carbamic acid derivatives
US6803381B1 (en) * 1999-04-20 2004-10-12 Hoffmann-La Roche Inc. Carbamic acid derivatives

Also Published As

Publication number Publication date
AU2003298195B2 (en) 2009-04-02
ES2265600T3 (es) 2007-02-16
US7119113B2 (en) 2006-10-10
JP2006512343A (ja) 2006-04-13
KR100713265B1 (ko) 2007-05-04
JP4286788B2 (ja) 2009-07-01
MXPA05006657A (es) 2005-08-16
RU2345076C2 (ru) 2009-01-27
US20040132792A1 (en) 2004-07-08
PL377708A1 (pl) 2006-02-06
PL211061B1 (pl) 2012-04-30
CN1735610A (zh) 2006-02-15
CA2511337C (en) 2011-12-20
AU2003298195A1 (en) 2004-07-14
CA2511337A1 (en) 2004-07-08
AR042643A1 (es) 2005-06-29
WO2004056814A1 (en) 2004-07-08
BR0317714A (pt) 2005-11-22
EP1578746A1 (de) 2005-09-28
RU2005123328A (ru) 2006-02-27
DE60306202D1 (de) 2006-07-27
CN100336813C (zh) 2007-09-12
EP1578746B1 (de) 2006-06-14
AU2003298195B8 (en) 2009-04-23
KR20050087848A (ko) 2005-08-31
DE60306202T2 (de) 2007-06-06

Similar Documents

Publication Publication Date Title
CY2015036I2 (el) Νεα παραγωγα οξαζολιδινονης
ATE447404T1 (de) Substituierte benzazole und ihre verwendung als raf-kinase-hemmer
DK1954684T3 (da) Oxazol forbindelse og farmaceutisk sammensætning.
ATE532774T1 (de) Benzoxazole und oxazolopyridine als janus- kinasehemmer
DE60323060D1 (de) Thiazol- und oxazolderivaten als ppar modulatoren
ATE449605T1 (de) N3-alkylierte benzimidazol-derivate als mek- hemmer
DK1678185T3 (da) 2,3-dihydro-6-nitroimidazo[2,1-b]oxazolforbindelser til behandling af tuberkulose
ATE369356T1 (de) Pyridazinon-derivate als cdk2-hemmer
DE60315862D1 (de) Dihydropyridinonderivate als hne-inhibitoren
NO20054135D0 (no) Kipolinon/benzoksazin derivater og anvendelser derav
DE602005015204D1 (de) Oxadiazolonderivate als ppar-delta-agonisten
DE60324208D1 (de) Biarylsulfonamide als mmp-inhibitoren
NO20054674D0 (no) Benzotiazolderivatforbindelser, preperater og anvendelser
CR9144A (es) Formulaciones de benzoxazoles sustituidos
DE602004004230D1 (de) Klasse-D Verstärker
ATE434436T1 (de) Pestizide (dihalopropenyl) phenylalkyl- substituierte benzoxazol- und benzothiazol- derivate
ATE538787T1 (de) Benzimidazol-derivative als raf-kinase-hemmer
SE0301107L (sv) Kraftförstärkare
ATE525365T1 (de) Oxazol, derivate aus tetracyclinen
ATE337322T1 (de) Isoxazolin-derivate als antidepressiva
ATE329913T1 (de) Oxazole als mglur1 verstärker
NO20053726D0 (no) Forbindelser med prolyloligopeptidase-hemmende aktivitet
DE60304800D1 (de) Optischer Verstärker
ATE390419T1 (de) 2-(piperidin-4-yl)-4,5-dihydro-2h-pyridazin-3-o - derivate als pde4-inhibitoren
DE60309543D1 (de) Optischer Verstärker

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1578746

Country of ref document: EP